FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS
Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1615 results
First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC
Findings from final efficacy and safety analyses from the LIBRETTO-001 study
Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX
Findings from a retrospective cohort study
Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers
Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2
EMA Recommends Extension of Therapeutic Indications for Durvalumab
New indication concerns treatment of adults with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer
Evidence for efficacy is based on the results from the DESTINY-Breast06 study
Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers
Findings from a systematic review of published studies
Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear Cell Gynaecological Cancers
Findings from the PEACOCC study
Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
Findings from the CEPHEUS study
EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel
New indication concerns treatment of adult patients with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer
Evidence for efficacy is based on the results from the TROPION-Breast01 study
Strong Independent Association of TILs with OS for Patients with ERBB2-positive Early Breast Cancer
Findings from updated analysis of the ShortHER study